Key statistics
On Friday, Alvotech SA (ALVO:ICX) closed at 1,737.50, 43.00% above the 52 week low of 1,215.00 set on Nov 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1,765.00 |
---|---|
High | 1,765.00 |
Low | 1,720.00 |
Bid | 1,730.00 |
Offer | 1,745.00 |
Previous close | 1,765.00 |
Average volume | 289.86k |
---|---|
Shares outstanding | 301.48m |
Free float | 107.18m |
P/E (TTM) | -- |
Market cap | 3.83bn USD |
EPS (TTM) | -2.65 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 16:00 GMT.
More ▼
Announcements
- Alvotech fundar með fjárfestum á heilbrigðisráðstefnum Citi og Evercore fjárfestingabankanna dagana 4. og 5. desember 2024
- Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
- Lyfjastofnun Evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir AVT05, fyrirhugaða líftæknilyfjahliðstæðu við Simponi (golimumab)
- European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
- Alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13. nóvember nk. og streyma uppgjörsfundi fimmtudaginn 14. nóvember nk. kl. 13:00 að íslenskum tíma
- Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
- Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
- Alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu Jefferies í London 19.-20. nóvember 2024
- Alvotech veitt aukið markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn), líftæknilyfjahliðstæðu við Stelara, til meðferðar sjúkdóma í meltingarvegi
- Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
More ▼